<DOC>
	<DOCNO>NCT00563355</DOCNO>
	<brief_summary>The primary aim study evaluate effect correction anemia use erythropoietin progression atherosclerosis cardiac muscle thicken patient chronic kidney disease</brief_summary>
	<brief_title>A Study Evaluate Whether Correction Anemia Using Recombinant Human Erythropoietin Reduces Progression Atherosclerosis Cardiac Hypertrophy Pre-dialysis Chronic Kidney Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients chronic renal failure serum creatinine 150umol/L 800umol/L time Hb Patients regression line 1/serum creatinine versus time showing may require dialysis within come 12 month Patients age 75 Patients valvular heart disease/congenital heart disease Patients ischemic heart disease/history myocardial infarction/coronary artery bypass surgery Patients history heart failure Patients regression line 1/serum creatinine versus time show estimate date end stage renal disease within 12 month Patients thalassemic trait haemoglobinopathy Patients underlie haematological malignancy Patients active bleeding Patients uncorrected iron vitamin deficiencies Patients poor general condition</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>chronic kidney disease</keyword>
	<keyword>cardiovascular disease</keyword>
</DOC>